Merger for Xenova and Cantab Pharma

Published: 2-Mar-2001


Xenova has agreed a share offer for Cantab, in a deal which values the new company at £123m (US$170m).

The merged company will work in the therapeutic areas of cancer, infectious diseases and addiction.

Cantab's future has been the source of much speculation recently, with deals with Provalis and Powderject having been projected.

The new company will employ 163 people, 30 less than the current figure.

You may also like